ProShare Advisors LLC Sells 3,127 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

ProShare Advisors LLC trimmed its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 18.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,920 shares of the company’s stock after selling 3,127 shares during the period. ProShare Advisors LLC’s holdings in IDEAYA Biosciences were worth $489,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Light Asset Management LLC purchased a new position in IDEAYA Biosciences during the 4th quarter worth $12,299,000. Superstring Capital Management LP acquired a new stake in IDEAYA Biosciences in the fourth quarter worth about $8,941,000. Vanguard Group Inc. grew its stake in shares of IDEAYA Biosciences by 17.0% during the fourth quarter. Vanguard Group Inc. now owns 3,475,772 shares of the company’s stock worth $123,668,000 after acquiring an additional 504,275 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of IDEAYA Biosciences during the first quarter valued at about $679,000. Finally, Jennison Associates LLC purchased a new position in shares of IDEAYA Biosciences in the 1st quarter valued at approximately $11,244,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IDYA has been the topic of a number of recent analyst reports. Mizuho started coverage on shares of IDEAYA Biosciences in a research note on Monday, July 8th. They set an “outperform” rating and a $50.00 price target on the stock. Citigroup cut their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating on the stock in a research report on Tuesday, August 27th. Wedbush lowered their price target on IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating for the company in a research report on Tuesday, September 24th. Stifel Nicolaus increased their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a report on Tuesday, September 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Twelve research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $56.00.

IDEAYA Biosciences Price Performance

Shares of NASDAQ IDYA opened at $31.68 on Tuesday. The firm’s 50 day simple moving average is $37.70 and its 200-day simple moving average is $39.09. IDEAYA Biosciences, Inc. has a 12 month low of $23.41 and a 12 month high of $47.74. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -15.76 and a beta of 0.84.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.52%. During the same quarter in the previous year, the firm posted ($0.50) earnings per share. Analysts anticipate that IDEAYA Biosciences, Inc. will post -2.51 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.